METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to slow prostate cancer spread
Disease control Recruiting nowThis study tests whether adding an experimental drug called PDS01ADC to standard chemotherapy (docetaxel) can help men with prostate cancer that has spread to other parts of the body. About 86 men with either castration-sensitive or castration-resistant metastatic prostate cancer…
Matched conditions: METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New trial: could adding chemo to hormone therapy stop prostate cancer from spreading?
Disease control Recruiting nowThis phase 3 trial is testing whether adding the chemotherapy drug docetaxel to standard hormone therapy (ADT plus an ARPI) can lower the chance of prostate cancer growing or spreading. The study enrolls 830 men with metastatic prostate cancer that is sensitive to hormone therapy…
Matched conditions: METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New shot every 12 weeks could help men with advanced prostate cancer
Disease control Recruiting nowThis study tests a new medicine called PRL-02 depot, given as a shot into the muscle every 12 weeks, for men with advanced prostate cancer. The drug lowers testosterone, which can help control the cancer. The study aims to find a safe dose and see how well men tolerate it, either…
Matched conditions: METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Double scan strategy aims to unlock prostate cancer secrets
Knowledge-focused Recruiting nowThis study involves 30 men with advanced prostate cancer who will receive two different PET scans (PSMA and FDG) to see how their tumors behave at different stages and during treatment. The goal is not to treat the cancer directly, but to gather information that could help doctor…
Matched conditions: METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC